EUCTR2013-002081-39-FI进行中（未招募）不适用
A Phase I/II, Randomized, Observer-Blind, Multicenter Study to Evaluate Immunogenicity and Safety of Four Influenza Vaccines in Healthy Pediatric Subjects 6 to < 48 Months of Age.
ovartis Vaccines & Diagnostics AG0 个研究点目标入组 672 人开始时间: 2013年9月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 672
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Is a healthy subject, male or female, 6 through < 48 months of age at the time of enrollment, who has never previously received an influenza vaccine
- •2. Has parent(s) or legal guardian(s) who have given written informed consent after the nature of the study has been explained according to local regulatory requirements
- •3. Is in good health as determined by medical history, the outcome of a physical examination, and the clinical judgment of the Investigator
- •4. Is able to comply with all study procedures and is available for all clinic visits scheduled in the study (including parents or guardians)
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 672
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Has parent(s) or legal guardian(s) who are not able to comprehend and to follow all required study procedures for the duration of the study
- •2. Has parent(s) or legal guardian(s) who are not able to read or write and are not able to delegate a designated person (information of whom will be entered in the study file) who:
- •a. Is an impartial person of legal age who is willing and able to witness the informed consent procedures as required by the protocol,
- •b. Is willing and able to undergo Diary Card training, and
- •c. Is willing and able to collect information on the Diary Card on a daily basis during the Post-vaccination Period through day 50 per protocol requirements;
- •3. Is a child from whom the minimal blood volume cannot be obtained prior to randomization, at the discretion of the investigator
- •4. Known or suspected impairment/alteration of immune function, including:
- •a. Long-term oral or parenteral corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- •b. Any history of cancer chemotherapy
- •c. Receipt of immunostimulants within 60 days prior to day 1
- •d. Receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 3 months prior to day 1 or planned during the full length of the study
- •e. Known HIV infection or HIV-related disease
- •5. Has a history of Guillain–Barré syndrome
- •6. Has a bleeding disorder that would be a contraindication to intramuscular injection
- •7. Has a history of non-febrile seizures
- •8. Has a history of or clinically suspected developmental delay
- •9. Has a history of premature birth (<36 weeks of gestation) and/or low birth weight (<2.5 kg)
- •10. Had laboratory-confirmed influenza disease within 6 months prior to visit 1
- •11. Has received an antipyretic or analgesic in the past 24 hours prior to vaccination
- •12. Has medical history or any illness that, in the opinion of the Investigator, might interfere with the results of the study or pose additional risk to the individual because of participation in the study
- •13. Has a history of any anaphylactic reaction and/or serious allergic reaction to any component of the study vaccine (see section 5.1)
- •14. Has experienced acute disease and/or fever (i.e., body temperature measurement =38.0°C [=100.4°F]) within 3 days prior to vaccination.
- •15. Has been participating in any clinical trial with another investigational product 4 weeks prior to first study visit or intends to participate in another clinical study at any time during the conduct of this study
- •16. Is the child of research staff involved with the clinical study at this institution or is otherwise related to research staff or has household members who are research staff associated with the investigator.
研究者
相似试验
进行中（未招募）
1 期
Study to assess the immunogenicity and safety of GSK's meningococcal group B vaccine when administered concomitantly with GSK's meningococcal MenACWY conjugate vaccine in healthy subjects of 16-18 years of age.Active immunization against invasive meningococcal disease caused by 5 different serogroups of N. meningitidis by concomitant administration of meningococcal group B vaccine and meningococcal MenACWY conjugate vaccineMedDRA version: 20.0Level: PTClassification code 10027199Term: MeningitisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-003722-16-ITGLAXOSMITHKLINE BIOLOGICALS945
进行中（未招募）
不适用
Evaluate the Safety, Tolerability, and Immunogenicity of Fluad and AgrifluPrevent the attack rates of influenza during both pandemic and interpandemic periods..EUCTR2014-005053-40-Outside-EU/EEAovartis Vaccines and Diagnostics S.r.l5,750
进行中（未招募）
不适用
A study to determine the immunogenicity and safety profile of CSL Limited's Influenza Virus Vaccine compared to a US licensed comparator Influenza Virus Vaccine in a pediatric population aged greater than or equal to 6 months to less than 18 years.Influenza, humanEUCTR2014-003768-19-Outside-EU/EEACSL Limited1,350
终止
1 期
A Clinical Trial to Assess the safety and immunogenicity of a combined Tetanus, Diphtheria, Acellular Pertussis and Poliomyelitis Vaccine (SIIPL Tdap-IPV) compared with Boostrix-IPV in Healthy Adults, Adolescents and ChildreTetanusDiphtheriaPertussisACTRN12620000848909Serum Institute of India Pvt Ltd107
进行中（未招募）
不适用
Evaluation of the safety and immunogenicity of GlaxoSmithKline Biologicals’ HPV vaccine 580299 when administered in healthy females aged 9 - 25 years using an alternative schedule and an alternative dosing as compared to the standard schedule and dosingFor active immunization of females for the prevention of cervical cancer by protecting against persistent infections, cytological abnormalities including atypical squamous cells of undetermined significance (ASC-US), cervical intraepithelial neoplasia (CIN) and pre-cancerous lesions (CIN 2/3) caused by oncogenic human papillomavirus (HPV) types 16 and 18.MedDRA version: 14.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 100000004862EUCTR2007-002777-32-DEGlaxoSmithKline Biologicals960